PfizerAnd BioNTechClinical trial data released Monday showed that the three-dose Covid vaccine, which is available for children aged six months to five years old, was effective in preventing illness from occurring during the Omicron Wave.

According to the companies, the third dose of the vaccine generated a strong immune response. It was also well tolerated by children with most side effects moderate to mild.

Ugur Sahin from BioNTech stated that they plan to submit their applications to the Food and Drug Administration this week. Albert Bourla, CEO of Pfizer, said that he hopes the vaccine is available for younger children as soon as it can.

These safety data were derived from 1,678 children aged under 5 who received another shot within two months of the first. This was when the main variant of omicron in circulation was omicron. Pfizer studied a small number of children under the age of 5 to assess their immune responses.

Three-microgram shots are given to children under five years of age. They receive one-tenth as many doses for adults.

Pfizer and Food and Drug Administration initially sought to expedite authorization for the first doses of vaccine in February, so that parents could get their children vaccinated as soon as possible. However, clinical trials results from the third dose were still being awaiting.

Bourla stated that Pfizer had delayed their application in order to receive data on the third dose, as the effectiveness of the previous two shots was only 30 to 40%. Bourla spoke to Bourla via podcast last month.

Only children below 5 years old are eligible to receive vaccinations in the U.S. Patients have waited for months before the FDA authorized shots.

Children younger than 5 years old were admitted to hospital with Covid during the huge wave of omicron infections that occurred in the winter. This was five times more than the peak rate for the pandemic. according to the Centers for Disease Control and Prevention.As of February 2015, Covid had infected 75% of children under 11 years old. according to CDC data.

ModernaThe FDA has been contacted by the FDA as well.uthorize its two-dose vaccine for children under age 6. The vaccine proved to be effective in protecting children younger than 6 years of age against infection with omicron. Moderna believes that vaccines should offer high levels of protection against serious illness because they produce antibodies.

FDA’s independent committee of vaccine experts plans to meet in JuneModerna and Pfizer applications will be considered. Promised dates are June 8-21, 22 and 22. Bourla stated that he hopes Pfizer will approve the vaccine for children under five in June.